Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Purchase individual online access for 1 year to this journal.
Price: EUR 595.00Impact Factor 2024: 3.4
The Journal of Alzheimer’s Disease is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease.
The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease.
Authors: Atwood, Craig S. | Smith, Mark A. | Bowen, Richard L.
Article Type: Letter
DOI: 10.3233/JAD-2005-7101
Citation: Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 1-2, 2005
Authors: Fasulo, Luisa | Ugolini, Gabriele | Cattaneo, Antonino
Article Type: Research Article
Abstract: Pathological changes in the microtubule associated protein tau are a major hallmark of many human dementias collectively defined as tauopathies. In familiar frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), several mutations in the tau gene have been identified showing that primary malfunction of tau can lead to neurodegeneration. In addition to mutation at genetic level, a number of post-translational modifications of tau occur in tauopathies, including abnormal phosphorylation and aberrant proteolysis described in Alzheimer's Disease (AD). The presence of cleaved tau in AD neurons is associated with expression of markers for neuronal death. According to our previous …work, tau is a substrate for the apoptotic protease caspase-3 that turns tau itself into an effector of apoptosis (tau cleaved at D-421), generating a positive-feedback loop that is self-propagating. Cleavage of tau by caspase-3 was recently confirmed to occur in AD brain as an early event. Here we show the apoptotic properties of tau fragment tau151-421 in primary cultures of rat hippocampal neurons; such cellular model is of special interest considering the selective vulnerability of hippocampal neurones in AD. The apoptotic capacity of tau151-421 is markedly enhanced by both treatment with amyloid peptide Aβ25–35, and the FTDP-17 tau mutation N279K. Show more
Keywords: tau, tauopathies, FTDP-17, apoptosis, caspase-3, AD
DOI: 10.3233/JAD-2005-7102
Citation: Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 3-13, 2005
Authors: Brown, Maile R. | Bondada, Vimala | Keller, Jeffery N. | Thorpe, Jeffery | Geddes, James W.
Article Type: Research Article
Abstract: Impaired tau catabolism may contribute to tau accumulation and aggregation in Alzheimer's disease and neurofibrillary tangle formation. This study examined the effects of proteasome and calpain inhibition on tau levels and turnover in primary rat hippocampal neurons and differentiated SH-SY5Y human neuroblastoma cells. Administration of proteasome (MG-115, lactacystin) or calpain (MDL28170) inhibitors for up to 24 hours did not alter tau levels in differentiated SH-SY5Y cells or rat hippocampal neurons. Addition of 1 μM and 10 μM MG-115 did not change total tau levels, but did result in increased reactivity of phosphorylation-dependent tau antibodies (PHF-1, CP-13) and decreased Tau-1 immunoreactivity. …Administration of cycloheximide to inhibit de novo protein synthesis also did not alter tau levels in the presence or absence of lactacystin. These results demonstrate that although the proteasome and calpain protease systems are capable of degrading tau in cell-free assays, their inhibition does not alter cellular tau levels in primary neurons or differentiated neuroblastoma cells. Show more
Keywords: Alzheimer's disease, catabolism, cysteine endopeptidases, neurofibrillary tangles, turnover
DOI: 10.3233/JAD-2005-7103
Citation: Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 15-24, 2005
Authors: Chen, Shuang | Averett, Natale T. | Manelli, Arlene | LaDu, Mary Jo | May, Warren | Ard, March D.
Article Type: Research Article
Abstract: Inflammation mediated by activated microglia cells has been shown to contribute to the pathogenesis of Alzheimer disease (AD) [1]. Microglia are the immune cells in the central nervous system, and when activated they secrete the lipid-derived mediator prostaglandin E2 (PGE2), the cytokine interleukin-1β (IL-1β), and other inflammatory mediators. Apolipoprotein E isoform 4 (apoE4), coded for by the gene APOE4 (ε4), has been shown to correlate with higher risk of onset of AD, as well as with increased severity of other diseases with a neuroinflammatory component. This study investigated isoform-specific effects of apoE on the regulation of PGE2, COX2, and IL-1β …expression. Two physiologically relevant preparations of apoE displayed an isoform-specific effect on inflammation in primary adult microglia cultured from adult rat brain cortex. Specifically, apoE4 alone, but not the more common isoform apoE3, stimulated secretion of PGE2 and IL-1β. The increase in PGE2 release stimulated by apoE4 was not accompanied by the upregulation of the COX-2 enzyme in microglia. Show more
Keywords: ApoE4, microglia, inflammation, prostaglandin, interleukin, neuroinflammation
DOI: 10.3233/JAD-2005-7104
Citation: Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 25-35, 2005
Authors: Chauhan, Ved | Sheikh, Ashfaq M. | Chauhan, Abha | Spivack, Warren D. | Fenko, Michael D. | Malik, Mazhar N.
Article Type: Research Article
Abstract: The effect of soluble amyloid beta-protein (sAβ) and fibrillar amyloid beta-protein (fAβ) on the casein-digesting activity of high molecular weight bovine brain protease (HMW protease) and trypsin was studied. While sAβ stimulated the casein-digesting activity of HMW protease in a concentration-dependent manner, it did not affect trypsin activity. Structure-activity relationship was studied by testing different soluble and fibrillar Aβ peptides. Various Aβ peptides affected casein-digesting activity of HMW protease differently: sAβ 1–40 > sAβ 22–35 = sAβ 1–11 = sAβ1–16 > sAβ 1–28 = sAβ 31–35, while sAβ 12–28 and sAβ 25–35 had no effect. On the other hand, among …the fibrillar Aβ peptides, only fAβ 1–40 significantly inhibited the casein-digesting activity of HMW protease. Tricine gel electrophoresis showed that sAβ was digested by trypsin while it remained un-cleaved in the presence of HMW protease. However, fAβ, a major component of amyloid plaques in Alzheimer's disease, inhibited the casein-digesting activity of both HMW protease and trypsin. fAβ was found to be resistant to proteolysis by HMW protease and trypsin. The trypsin resistance starts in the early stage of fibrillization of Aβ, i.e., aggregated Aβ. Taken together, these results suggest that fibrillization of Aβ may affect the clearance of Aβ by inhibiting the brain proteases, thereby increasing the concentration of circulating Aβ, that may further increase the Aβ fibrillization. Show more
Keywords: amyloid beta-protein, fibrillization, high molecular weight protease, proteolysis, trypsin
DOI: 10.3233/JAD-2005-7105
Citation: Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 37-44, 2005
Authors: de la Monte, Suzanne M. | Wands, Jack R.
Article Type: Research Article
Abstract: Interest in characterizing the role of impaired insulin actions in Alzheimer's disease (AD) and vascular dementia is growing exponentially. This review details what is currently known about insulin, insulin-like growth factor type I (IGF-I) and IGF-II proteins and their corresponding receptors in the brain, and delineates the major controversies pertaining to alterations in the expression and function of these molecules in AD. The various experimental animal models generated by over-expression, mutation, or depletion of genes that are critical to the insulin or IGF signaling cascades are summarized, noting the degrees to which they reproduce the histopathological, biochemical, molecular, or behavioral …abnormalities associated with AD. Although no single model was determined to be truly representative of AD, depletion of the neuronal insulin receptor and intracerebroventricular injection of Streptozotocin reproduce a number of important aspects of AD-type neurodegeneration, and therefore provide supportive evidence that AD may be caused in part by neuronal insulin resistance, i.e. brain diabetes. The extant literature did not resolve whether the CNS insulin resistance in AD represents a local disease process, or complication/extension of peripheral insulin resistance, i.e. chronic hyperglycemia, hyperinsulinemia, and Type 2 diabetes mellitus. The available epidemiological data are largely inconclusive with regard to the contribution of Type 2 diabetes mellitus to cognitive impairment and AD-type neurodegeneration. A major conclusion drawn from this review is that there is a genuine need for thorough and comprehensive study of the neuropathological changes associated with diabetes mellitus, in the presence or absence of superimposed AD or vascular dementia. Strategies for intervention may depend entirely upon whether the CNS disease processes are mediated by peripheral, central, or both types of insulin resistance. Show more
Keywords: diabetes mellitus, insulin resistance, Alzheimer's disease, animal models, insulin like growth factor, signal transduction, review
DOI: 10.3233/JAD-2005-7106
Citation: Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 45-61, 2005
Authors: Steen, Eric | Terry, Benjamin M. | J. Rivera, Enrique | Cannon, Jennifer L. | Neely, Thomas R. | Tavares, Rose | Xu, X. Julia | Wands, Jack R. | de la Monte, Suzanne M.
Article Type: Research Article
Abstract: The neurodegeneration that occurs in sporadic Alzheimer's disease (AD) is consistently associated with a number of characteristic histopathological, molecular, and biochemical abnormalities, including cell loss, abundant neurofibrillary tangles and dystrophic neurites, amyloid-β deposits, increased activation of pro-death genes and signaling pathways, impaired energy metabolism/mitochondrial function, and evidence of chronic oxidative stress. The general inability to convincingly link these phenomena has resulted in the emergence and propagation of various heavily debated theories that focus on the role of one particular element in the pathogenesis of all other abnormalities. However, the accumulating evidence that reduced glucose utilization and deficient energy metabolism occur …early in the course of disease, suggests a role for impaired insulin signaling in the pathogenesis of AD. The present work demonstrates extensive abnormalities in insulin and insulin-like growth factorm typer I and II (IGF-I and IGF-II) signaling mechanisms in brains with AD, and shows that while each of the corresponding growth factors is normally made in central nervous system (CNS) neurons, the expression levels are markedly reduced in AD. These abnormalities were associated with reduced levels of insulin receptor substrate (IRS) mRNA, tau mRNA, IRS-associated phosphotidylinositol 3-kinase, and phospho-Akt (activated), and increased glycogen synthase kinase-3β activity and amyloid precursor protein mRNA expression. The strikingly reduced CNS expression of genes encoding insulin, IGF-I, and IGF-II, as well as the insulin and IGF-I receptors, suggests that AD may represent a neuro-endocrine disorder that resembles, yet is distinct from diabetes mellitus. Therefore, we propose the term, "Type 3 Diabetes" to reflect this newly identified pathogenic mechanism of neurodegeneration. Show more
Keywords: diabetes, insulin signaling, insulin gene expression, central nervous system, Alzheimer's disease, glycogen synthase kinase, growth factor receptors, real time RT-PCR
DOI: 10.3233/JAD-2005-7107
Citation: Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 63-80, 2005
Authors: Zhu, Xiongwei | Perry, George | Smith, Mark A.
Article Type: Article Commentary
DOI: 10.3233/JAD-2005-7108
Citation: Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 81-84, 2005
Article Type: Discussion
DOI: 10.3233/JAD-2005-7109
Citation: Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 85-91, 2005
Article Type: Book Review
DOI: 10.3233/JAD-2005-7110
Citation: Journal of Alzheimer's Disease, vol. 7, no. 1, pp. 93-93, 2005
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl